• Explore /
  • Poster
  • / Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).

Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance).

Abstract Poster

Authors

Susan Halabi

Susan Halabi

Duke University Medical Center, Durham, NC

Susan Halabi , Qian Yang , Mark D. Starr , John C. Brady , Andrew J. Armstrong , Daniel J. George , William Kevin Kelly , Himisha Beltran , Michael J. Morris , Andrew B. Nixon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Advanced Disease

Track

Prostate Cancer - Advanced

Sub Track

Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 154)

DOI

10.1200/JCO.2021.39.6_suppl.154

Abstract #

154

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Simon J. Crabb

First Author: Thais Caroline Menegasso Flores

First Author: Angeles Alvarez Secord

First Author: Karen A. Autio